Tech Company Financing Transactions
CorFlow Therapeutics Funding Round
CorFlow Therapeutics secured a $49 million Series B funding round on 9/10/2024. Backers included Broadview Ventures, Panakes Partners and 415 CAPITAL.
Transaction Overview
Company Name
Announced On
9/10/2024
Transaction Type
Venture Equity
Amount
$49,000,000
Round
Series B
Investors
Broadview Ventures (Lead Investor) (David Prim)
Panakes Partners (Lead Investor) (Barbara Castellano)
Proceeds Purpose
The company intends to use the funds to accelerate the MOCA II (MVO with CoFITM System Assessment II) pivotal study intended to gain US market clearance. The trial will run in the US and Europe and aims to validate its CoFl system to diagnose MVO in heart attack patients immediately following stent implantation.
Company Information
Company Status
Private & Independent
Industry
Medical Devices & Instruments
Mailing Address
Neuhofstrasse 3d
Baar, 6340
Switzerland
Baar, 6340
Switzerland
Phone
Website
Email Address
Overview
To be the leader in diagnostic and therapeutic solutions for restoring healthy microvascular blood flow anywhere in the human body where a critical need exists.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Rick Geoffrion
Chief Executive Officer
Paul Mead
Chief Operating Officer
Oliver Bludau
Chief Scientific Officer
Sabrina Frey
VP - Product Management
Lukas Bereuter
VP - Regulatory Affairs
Markus Bütler
Browse more venture capital transactions:
Prev: 9/10/2024: Cerrion venture capital transaction
Next: 9/10/2024: NanoSyrinx venture capital transaction
Share this article
News on VC Transactions
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs